QRX003
Netherton Syndrome
Key Facts
About Quoin Pharmaceuticals
Quoin Pharmaceuticals is a clinical-stage company dedicated to addressing critical unmet needs in rare and orphan diseases, with a primary focus on severe skin barrier defects and vascular malformations. Its core achievement is the development of proprietary topical delivery systems for rapamycin, leading to its lead candidate, QRX003, which has secured multiple regulatory designations (Orphan Drug in US/EU, Rare Pediatric Disease) and is advancing in pivotal studies for Netherton Syndrome. The company's strategy combines targeted internal commercial infrastructure in key markets (US, Western Europe, Japan) with a network of nine exclusive marketing and distribution partnerships covering 61 additional countries to maximize global reach for its pipeline.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| ATR-12 | Azitra | Phase 1 |
| QRX003 (via Quoin Pharmaceuticals) | Skinvisible Pharmaceuticals | Clinical Trials |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| SXR1096 | Sixera Pharma | Phase 1 |
| KB104 | Krystal Biotech | Preclinical |
| BCX17725 | BioCryst Pharmaceuticals | Pre-Clinical/Phase 1 |